Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
Jane Kirby

Brain cancer patients left ‘devastated’ as new drug is rejected for NHS use

Brain cancer patients have expressed disappointment after a drug that slows tumours from growing was rejected for use on the NHS.

Vorasidenib is for people aged 12 or over who have had surgery for types of low-grade glioma with either the IDH1 or IDH2 genetic mutations.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.